ALLEGATO B

UNIVERSITÀ DEGLI STUDI DI MILANO
selezione pubblica per n._1_ posto/i di Ricercatore a tempo determinato ai sensi dell'art.24, comma 3, lettera b) della Legge 240/2010 per il settore concorsuale _05/I2_____ , settore scientifico-disciplinare __BIO/19_____
presso il Dipartimento di ___SCIENZE FARMACOLOGICHE E BIOMOLECOLARI_____, (avviso bando pubblicato sulla G.U. n. _59_____ del _26/07/2022_____) Codice concorso _5074___

Silvio Notari
CURRICULUM VITAE

INFORMAZIONI PERSONALI

COGNOME **NOTARI**
NOME **SILVIO**
DATA DI NASCITA **09/11/1965**

TITOLI

TITOLO DI STUDIO

Laurea in Scienze Biologiche. Universita' di Bologna, 20/07/1993. Voto 110/110.

TITOLO DI DOTTORE DI RICERCA O EQUIVALENTI, OVVERO, PER I SETTORI INTERESSATI, DEL DIPLOMA DI SPECIALIZZAZIONE MEDICA O EQUIVALENTE, CONSEGUITO IN ITALIA O ALL'ESTERO

Dottorato di ricerca in Biologia e Fisiologia Cellulare, Universita' di Bologna, 05/05/1998. Tesi di dottorato: Modificazioni indotte dall'esposizione al freddo sul metabolismo delle poliammine, sulla neurotrasmissione aminoacidica, sulla permeabilita' della barriera emato-encefalica nel teleosteo d'acqua dolce *Carassius auratus*.

CONTRATTI DI RICERCA, ASSEGNI DI RICERCA O EQUIVALENTI

Assegno di ricerca: Dipartimento di Neurologia, Universita' di Bologna. Argomento: "Sviluppo di metodologie di analisi rapide e sensibili per la diagnosi molecolare, ceppo-specifica, della malattia di Creutzfledt-Jakob". Dal 01/01/2002 al 31/12/2003.

Assegno di ricerca: Dipartimento di Neurologia, Universita' di Bologna. Argomento: "Sviluppo di metodologie di analisi rapide e sensibili per la diagnosi molecolare, ceppo-specifica, della malattia di Creutzfledt-Jakob". Dal 01/01/2004 al 31/12/2005.

Contratto di Ricerca (Co.Co.Pro) presso il Dipartimento di Scienze Neurologiche, Universita' di Bologna. Dal 01/01/2006 al 31/12/2006.

Contratto di Ricerca (Co.Co.Pro) presso il Dipartimento di Scienze Neurologiche, Universita' di Bologna. Dal 01/01/2007 al 31/08/2007

ATTIVITÀ DIDATTICA A LIVELLO UNIVERSITARIO IN ITALIA O ALL'ESTERO

2014: Supervisione, di un Ricercatore (Research Associate) del Dipartimento di Patologia, Case Western Reserve University, OH, USA.

2015: Insegnamento, formazione e supervisione di un Postdoc Scholar e supervisione di un Ricercatore (Research Associate) del Dipartimento di Patologia, Case Western Reserve University, OH, USA.

2016: Formazione e supervisione di due Postdoc Scholars della Case Western Reserve University, OH, USA e di un Research Associate del Dipartimento di Patologia, Case Western Reserve University, OH, USA.

2017: Supervisione di un Postdoc Scholar della Case Western Reserve University, OH, USA e supervisione/formazione di un Tecnico di laboratorio (Research Assistant) del Dipartimento di Patologia, Case Western Reserve University, OH, USA.

2018: Supervisione di un Postdoc Scholar della Case Western Reserve University, OH, USA e formazione supervisione di un Tecnico di laboratorio (Research Assistant) del Dipartimento di Patologia, Case Western Reserve University, OH, USA.

DOCUMENTATA ATTIVITÀ DI FORMAZIONE O DI RICERCA PRESSO QUALIFICATI ISTITUTI ITALIANI O STRANIERI;

18/5/2008 - 31/08/2010: Ricercatore (Research Associate) presso il Dipartimento di Patologia (sede del National Prion Disease Pathology Surveillance Center of USA), Case Western Reserve University, OH, USA.

01/09/2010 - 30/06/2019: Instructor (Faculty position) presso il Dipartimento di Patologia (sede del National Prion Disease Pathology Surveillance Center of USA), Case Western Reserve University, OH, USA.

REALIZZAZIONE DI ATTIVITÀ PROGETTUALE

01/02/2014 - 31/01/2016: PROGETTAZIONE, ORGANIZZAZIONE, DIREZIONE, COORDINAMENTO E PARTECIPAZIONE ALLE ATTIVITA' DEL GRUPPO MULTICENTRICO DI RICERCA per il progetto “Spitz Award - Non-invasive, definitive and specific diagnosis in prion and other neurodegenerative diseases”; finanziamento "The Spitz Brain Health Innovation Fund # 14810.01.J0342.E.50326, USA."
Leader del progetto: Dr. Silvio Notari. Research Team: Silvio Notari(PI), Department of Pathology, Case Western Reserve University, Cleveland, OH, USA; Pierluigi Gambetti, Department of Pathology, Case Western Reserve University, Cleveland, OH, USA; Brian Appleby, Department of Neurology, University Hospital, Cleveland, OH, USA; Manuel Camacho, Department of Pathology, Case Western Reserve University, Cleveland, OH, USA; Kenneth Rodriguez, Otolaringology, University Hospital, Cleveland, OH, USA; Aaron Foutz Department of Pathology, Case Western Reserve University, Cleveland, OH, USA; Xiaoqin Liu, Department of Pathology, Case Western Reserve University, Cleveland, OH, USA; Gianluigi Zanusso, Department of Neurosciences, University of Verona, Italy; Byron Caughey, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, Hamilton, MT, USA. Attivita' di ricercar documentata da: 1 articolo (ultimo e corresponding author) e partecipazione ad 1 congresso.

01/01/2013 – 31/12/2014: PROGETTAZIONE, ORGANIZZAZIONE E PARTECIPAZIONE AL PROGETTO “Analyses of the protein tau to help determine whether the newly discovered protease-sensitive prionopathy is the sporadic form of Gerstmann-Sträussler-Scheinker disease (GSS).” Finanziato da Creutzfeldt-Jakob Disease Foundation, USA.

ORGANIZZAZIONE, DIREZIONE E COORDINAMENTO DI GRUPPI DI RICERCA NAZIONALI E INTERNAZIONALI, O PARTECIPAZIONE AGLI STESSI

01/07/2014 - 30/06/2019: PARTECIPAZIONE ALLE ATTIVITA' DEL GRUPPO MULTICENTRICO DI RICERCA NAZIONALE (USA) per il progetto “Mechanisms of human prion disease diversity”; finanziamento “National Institute of Health (USA) Grant P01 AI106705”, leader del progetto Prof. Pierluigi Gambetti, Department of Pathology, Case Western Reserve University, Cleveland, OH, USA. Attivita' di ricerca documentata da: 4 articoli (primo autore e/o corresponding author) e da partecipazione come relatore a 2 congressi di rilevanza internazionale.

01/07/2014 - 31/05/2019: PARTECIPAZIONE ALLE ATTIVITA' DEL GRUPPO MULTICENTRICO DI RICERCA NAZIONALE (USA) per il progetto “Structural correlates of prion strain, phenotype and infectivity in human prion”; finanziamento : National Institute of Health (USA) Grant R01 NS083687; leader del progetto Prof. Pierluigi Gambetti, Department of Pathology, Case Western Reserve University, Cleveland, OH, USA. Attivita' di ricerca documentata da: 4 articoli (primo autore e/o corresponding author) e da partecipazione come relatore a 2 congressi di rilevanza internazionale.

01/02/2014 - 31/01/2016: PROGETTAZIONE, ORGANIZZAZIONE, DIREZIONE, COORDINAMENTO E PARTECIPAZIONE ALLE ATTIVITA' DEL GRUPPO MULTICENTRICO DI RICERCA per il progetto “Spitz Award - Non-invasive, definitive and specific diagnosis in prion and other neurodegenerative diseases”; finanziamento "The Spitz Brain Health Innovation Fund # 14810.01.J0342.E.50326, USA." Leader del

progetto: Dr. Silvio Notari. Research Team: Silvio Notari (PI), Department of Pathology, Case Western Reserve University, Cleveland, OH, USA; Pierluigi Gambetti, Department of Pathology, Case Western Reserve University, Cleveland, OH, USA; Brian Appleby, Department of Neurology, University Hospital Cleveland, OH, USA; Manuel Camacho, Department of Pathology, Case Western Reserve University, Cleveland, OH, USA; Kenneth Rodriguez, Otolaringology, University Hospital, Cleveland, OH, USA; Aaron Foutz Department of Pathology, Case Western Reserve University, Cleveland, OH, USA; Xiaoqin Liu, Department of Pathology, Case Western Reserve University, Cleveland, OH, USA; Gianluigi Zanusso, Department of Neurosciences, University of Verona, Italy; Byron Caughey, Rocky Mountain Laboratories National Institute of Allergy and Infectious Diseases, Hamilton, MT, USA. Attivita' di ricercar documentata da: 1 articolo (ultimo e corresponding author) e partecipazione ad 1 congresso.

21/04/2008 - 31/08/2014: PARTECIPAZIONE ALLE ATTIVITA' DEL GRUPPO MULTICENTRICO DI RICERCA NAZIONALE (USA) per il progetto “Pathogenetic mechanisms of prion disease – Mechanisms of prion strain and phenotypic diversity””; finanziamento “National Institute of Health (USA) Grant P01AG014359, leader del progetto Prof. Pierluigi Gambetti, Department of Pathology, Case Western Reserve University, Cleveland, OH, USA. Attivita' di ricerca documentata da: 4 articoli (primo autore) e partecipazione come relatore (presentazione orale) a 2 congressi di rilevanza internazionale.

01/09/2003 - 31/08/2007: PARTECIPAZIONE ALLE ATTIVITA' DEL GRUPPO MULTICENTRICO DI RICERCA EUROPEO coordinato dal Dr. Jean-Philippe Deslys, per il progetto “Prevention, control and management of prion diseases”. Finanziamento: European Commission (Grant FOOD-CT-2004-506579). Attivita’ di ricerca documentata da: 2 articoli (primo autore) e partecipazione come relatore a 2 congressi di rilevanza internazionale.

30/10/2003 - 31/08/2007: PARTECIPAZIONE ALLE ATTIVITA' DEL GRUPPO MULTICENTRICO DI RICERCA NAZIONALE (ITA) per il progetto. Finanziamento Italian Ministry of University, Research and Technology, Grant FIRB-2003-BNE03FMCJ_006; leader del progetto Prof. Piero Parchi. Attivita’ di ricerca documentata da: 2 articoli (primo autore) e partecipazione come relatore a 2 congressi di rilevanza internazionale.

CONSEGUIMENTO DI PREMI E RICONOSCIMENTI NAZIONALI E INTERNAZIONALI PER ATTIVITÀ DI RICERCA

05/03/2014: SPITZ AWARD, per il progetto "Non-invasive, definitive and specific diagnosis in prion and other neurodegenerative diseases".
Ente emittente: Spitz Brain Health Innovation Fund.
Motivazione: "The project has a direct impact on diagnosis or outcomes in patients with memory, cognitive or behavioral dysfunction preferably in a well-defined patient population such as Alzheimer disease, Parkinson disease, traumatic brain injury, or other neurobehavioral disorders." The recipient of this award will be recognized as Spitz Scholars. Spitz projects should be multidisciplinary and should demonstrate relevance to the Case Brain Health Collaborative the goal of which is to foster interdisciplinary patient care, educational and research programs related to neurodegenerative disorders and brain health among CWRU colleges, schools, departments, and University Hospitals Case Medical Center consistent with the strategic plan for CWRU and the Health Care Alliance Initiative. The Spitz Scholars were established in 2011 by University Hospitals and the Case Brain Health Collaborative thanks to a generous gift from Virginia Spitz in remembrance of her husband Buddy (owner of the famous Theatrical Restaurant) who had Alzheimer's Disease.

PRODUZIONE SCIENTIFICA

PANORAMICA PUBBLICAZIONI

- **33** articoli in ISI peer-reviewed journals:
- **3** articoli come corresponding author + **10** articoli come primo autore
- **5** capitoli di libro (di cui **4** come primo o ultimo autore)

ARTICOLI IN RIVISTA

33. Nemani SK, Xiao X, Cali I, Cracco L, Puoti G, Nigro M, Lavrich J, Bharara Singh A, Appleby BS, Sim VL, **Notari S**, Surewicz WK, Gambetti P. A novel mechanism of phenotypic heterogeneity in Creutzfeldt-Jakob disease. *Acta Neuropathol Commun*. 2020 , 8:85. DOI: 10.1186/s40478-020-00966-x

32. Camacho MV, Telling G, Kong Q, Gambetti P, **Notari S.** Role of PrP glycosylation in replication of human prions by PMCA. *Lab Invest*. 2019, 99:1741–8. DOI: 10.1038/s41374-019-0282-1

31. Cracco L, Xiao X, Nemani SK, Lavrich J, Cali I, Ghetti B, **Notari S**, Surewicz WK, Gambetti P. Gerstmann-Sträussler-Scheinker disease revisited: Accumulation of covalently-linked multimers of internal prion protein fragments. *Acta Neuropathol Commun*. 2019, 7:1. DOI: 10.1186/s40478-019-0734-2

30. Cali I, Lavrich J, Moda F, Kofskey D, Nemani SK, Appleby B, Tagliavini F, Soto C, Gambetti P, **Notari S.** PMCA-replicated PrP^{D} in urine of vCJD patients maintains infectivity and strain characteristics of brain PrP^{D}: Transmission study. *Sci Rep*. 2019 9:5191. DOI: 10.1038/s41598-019-41694-0

29. Nonno R*, **Notari S***, Di Bari MA, Cali I, Pirisinu L, d'Agostino C, Cracco L, Kofskey D, Vanni I, Lavrich J, Parchi P, Agrimi U, Gambetti P. Variable protease sensitive prionopathy: Transmission to Bank Voles reveals multiple prion strains. *Emerg Infect Dis*. 2019; 25:73–81. DOI: 10.3201/eid2501.180807 **** Co-first authors***

28. Nemani SK*, **Notari S*§**, Cali I, Alvarez VE, Kofskey D, Cohen M, Stern RA, Appleby B, Abrams J, Schonberger L, McKee A , Gambetti P**§**. Co-occurrence of chronic traumatic encephalopathy and prion disease. *Acta Neuropathol Commun*. 2018; 6:140. DOI: 10.1186/s40478-018-0643-9 **** Co-first authors ; § Co-corresponding authors***

27. Cracco L, **Notari S**, Cali I, Sy MS, Chen SG, Cohen ML, Ghetti B, Appleby BS, Zou WQ, Byron W. Caughey BW, Jiri G. Safar JG, Gambetti P. Novel strain properties distinguishing subtypes of sporadic prion disease sharing prion protein genotype and prion type. *Sci Rep*. 2017; 7:38280. DOI: 10.1038/srep38280

26. Umeh CC Kalakoti P, Greenberg MK, **Notari S**, Cohen Y, Gambetti P, Oblak AL, Ghetti B and Mari Z. Clinicopathological Correlates in a PRNP P102L Mutation Carrier with Rapidly Progressing Parkinsonism-Dystonia. *Mov Disord Clin Pract*. 2016; 3:355–8. DOI: 10.1002/mdc3.12307

25. Ghoshal N, Perry A, McKeel D, Schmidt RE, Carter D, Norton J, Zou WQ, Xiao X, Puoti G, **Notari S,** Gambetti P, Morris JC, Cairns NJ. Variably protease-sensitive prionopathy in an apparent cognitively normal 93 year old. *Alzheimer Dis Assoc Disord*. 2015; 29:173–6. DOI: 10.1097/WAD.0000000000000049

24. Cardone F, Serena P, Schinina ME, Maras B, Capellari S, Parchi P, **Notari S**, DiFrancesco L, Poleggi A, Galeno R, Vinci R, Mellina V, Almonti S, La Dogana A, Pocchiari M. Mutant PrP^{CJD} prevails over wild-type PrP^{CJD} in the brain of V210I and R208H genetic Creutzfeldt-Jakob disease patients. *Biochem Biophys Res Commun*. 2014; 454:289–94. DOI: 10.1016/j.bbrc.2014.10.051

23. **Notari S**, Xiao X, Espinosa JC, Cohen Y, Qing L, Aguilar-Calvo P, Kofskey D, Cali I., Cracco L, Kong Q, Torres JM, Zou WQ, Gambetti P. Transmission characteristics of variably protease sensitive prionopathy. Emerg Infect Dis. 2014; 20:2006–14. DOI: 10.3201/eid2012.140548

22. Moda F, Gambetti P, **Notari** S, Concha-Marambio L, Catania M, Park KW, Maderna E, Suardi S, Haïk S, Brandel JP, Ironside J, Knight R, Tagliavini F, **Soto** C. Prions in the urine of patients with variant Creutzfeldt-Jakob disease. *N Engl J Med*. 2014; 371:530–9. DOI: 10.1056/NEJMoa1404401

21. Cannon A, Bieniek K, Lin WL, **Notari S**, Zou WQ, Gambetti P, Pedraza O, Graff-Radford NR, Ferman TJ, Dickson DW. Concurrent prion disease and amyotrophic lateral sclerosis. *Acta Neuropathol*. 2014; 128:313–5. DOI: 10.1007/s00401-014-1309-8

20. Saverioni D, **Notari S**, Capellari S, Poggiolini I, Giese A, Kretzschmar HA, Parchi P. Analyses of protease-resistance and aggregation state of abnormal prion protein across the spectrum of human prions. *J Biol Chem*. 2013; 288:27972–85. DOI: 10.1074/jbc.M113.477547

19. **Notari S**, Qing L, Pocchiari M, Dagdanova A, Hatcher K, Dogterom A, Groisman JF, Lumholtz B, Puopolo M, Lasmezas C, Chen SG, Kong Q, Gambetti P. Assessing prion infectivity of urine in sporadic Creutzfeldt-Jakob disease. *Emerg Infect Dis*. 2012; 18:21–8. DOI: 10.3201/eid1801.110589

18. Gambetti P, Cali I, **Notari S**, Kong Q, Zou WQ, Surewicz W.K. Molecular biology and pathology of prion strains in sporadic human prion diseases. *Acta Neuropathol*. 2011; 121:79–90. DOI: 10.1007/s00401-010-0761-3

17. Dagdanova A*, Ilchenko S*, **Notari S***, Yang Q, Obrenovich ME, Hatcher K, McAnulty P, Huang L, Zou W, Kong Q, Gambetti P, Chen SG. Characterization of prion protein in human urine. *J Biol Chem*. 2010; 285:30489–95. DOI: 10.1074/jbc.M110.161794
**** Co-first authors***

16. Parchi P, Cescatti M, **Notari S**, Schulz-Schaeffer Q, Capellari S, Giese A, Zou WQ, Kretzschmar H, Ghetti B, Brown P. Agent strain variation in human prion disease: Insights from a molecular and pathological revision of the National Institutes of Health series of experimentally transmitted disease. *Brain*. 2010; 133:3030–42. DOI: 10.1093/brain/awq234.

15. Zou WQ, Puoti G, Xiao X, Yuan J, Qing L, Cali I, Shimoji M, Langeveld JP, Castellani R, **Notari S**, Crain B, Schmidt RE, Geschwind M, Dearmond SJ, Cairns NJ, Dickson D, Honig L, Torres JM, Mastrianni J, Capellari S, Giaccone G, Belay ED, Schonberger LB, Cohen M, Perry G, Kong Q, Parchi P, Tagliavini F, Gambetti P. Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. *Ann Neurol*. 2010; 68:162–72. DOI: 10.1002/ana.22094

14. **Notari S**, Moleres JM, Hunter SB, Belay ED, Schonberger LB, Cali I, Parchi P, Shieh WJ, Zaki SR, Zou WQ, Gambetti P. Multi-organ detection and characterization of the protease-resistant prion protein in a case of variant Creutzfeldt–Jakob disease examined in the United States. *PLoS One*. 2010; 5(1). DOI: e8765. 10.1371/journal.pone.0008765

13. Parchi P, Strammiello R, **Notari S**, Giese A, Langeveld JP, Ladogana A, Zerr I, Roncaroli F, Cras P, Ghetti B, Pocchiari M, Kretzschmar H, Capellari S. Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification. *Acta Neruopathol*. 2009; 118:659–71. DOI: 10.1007/s00401-009-0585-1

12. Parchi P, **Notari S**, Weber P, Schimmel H, Budka H, Ferrer I, Haik S, Hauw JJ, Head MW, Ironside JW, Limido L, Rodriguez A, Ströbel T, Tagliavini F, Kretzschmar HA. Inter-laboratory assessment of PrP^{Sc} typing in Creutzfeldt-Jakob disease: a Western blot study within the NeuroPrion Consortium. *Brain Pathol*. 2009; 19:384–91. DOI: 10.1111/j.1750-3639.2008.00187.x.

11. **Notari S**, Strammiello R, Capellari S, Giese A, Grassi J, Ghetti B, Gambetti P, Kretzschmar HA, Parchi P. Characterization of novel truncated forms of abnormal prion protein in Creutzfeldt-Jakob disease. *J Biol Chem*. 2008; 283:30557–65. DOI: 10.1074/jbc.M801877200.

10. **Notari S**, Capellari S, Langeveld J, Giese A, Strammiello R, Gambetti P, Kretzschmar HA, Parchi P. A refined method for molecular typing reveals that co-occurrence of PrP^{Sc} types in Creutzfeldt–Jakob disease is not the rule. *Lab Invest*. 2007; 87:1103–12. DOI: 10.1038/labinvest.3700676

9. Capellari S, Cardone F, **Notari S**, Schininà ME, Maras B, Sità D, Baruzzi A, Pocchiari M, Parchi P. Creutzfeldt-Jakob disease associated with the R208H mutation in the prion protein gene. *Neurology*. 2005; 64:905–7. DOI: 10.1212/01.WNL.0000152837.82388.DE

8. **Notari S**, Capellari S, Giese A, Westner I, Baruzzi A, Ghetti B, Gambetti P, Kretzschmar HA, Parchi P. Effects of different experimental conditions on the PrP^{Sc} core generated by protease digestion: implications for strain typing and molecular classification of CJD. *J Biol Chem*. 2004; 279:16797–804. DOI: 10.1074/jbc.M313220200

7. **Notari S**, Lucchi R, Traversa U, Fabbri E, Poli A. Reversible changes in goldfish brain polyamine concentrations and synthetic enzymes after cold exposure. *Brain Res*. 2004; 1006:241–7. DOI: 10.1016/j.brainres.2004.01.073
6. Poli A, Di Iorio P, Beraudi A, **Notari S**, Zaccanti F, Villani L, Traversa U. The calcium-dependent ^{3}[H]acetylcholine release from synaptosomes of brown trout (Salmo trutta) optic tectum is inhibited by adenosine A_1 receptors. Effects of enucleation on A_1 receptor density and cholinergic markers. *Brain Res*. 2001; 892:78–85. DOI: 10.1016/s0006-8993(00)03229-7
5. Poli A, Lucchi R**, Notari S**, Zampacavallo G, Gandolfi O, Traversa U. Pharmacological characterization of adenosine A_1 receptor and its functional role in brown trout (Salmo trutta) brain. *Brain Res*. 1999; 837:46–54. DOI: 10.1016/s0006-8993(99)01701-1
4. Poli A, Lucchi R, Storto M, De Paolis P, **Notari S,** Nicoletti F, Casabona G. Predominant expression of group-II metabotropic glutamate receptors in the goldfish brain. *Brain Res*. 1999; 834:142–5. DOI: 10.1016/s0006-8993(99)01518-8.
3. **Notari S**, Lucchi R, Poli A. Effect of cold exposure on polyamine levels and ornithine decarboxylase activity of goldfish tissue. *Cell Mol Life Sci*. 1998; 54:277–81.
2. Lucchi R, **Notari S**, Pierantozzi S, Barnabei O, Poli A. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in goldfish cerebellum: neurochemical and immunocytochemical analysis. *Brain Res*. 1998; 782:105–12. DOI: 10.1016/s0006-8993(97)01272-9.
1. Poli A, **Notari S**, Virgili M, Fabbri E, Lucchi R. Neurochemical changes in cerebellum of goldfish exposed to various temperature. *Neurochem Res*. 1997; 22:141–9. DOI: 10.1023/a:1027307305595.

CAPITOLI DI LIBRI

5. **Notari S**, Appleby B, Pierluigi G. Variably protese sensitive prionopathy. *Handb Clin Neurol, Human prion diseases* (2018) pp 175-190, eds. Manson J and Pocchiari M. Publisher Elsevier BV, San Diego, USA. DOI: 10.1016/B978-0-444-63945-5.00010-6
4. **Notari S**, Yuan J, Bi H, Cali I, Kong Q, Zou WQ. Variant Creutzfeldt–Jakob Disease. *Reference Module in Neuroscience and Biobehavioral Psychology*, (2017) pp 1-6. Publisher Elsevier, Oxford, UK.
3. Gambetti P, **Notari S**. Sporadic human prion diseases. *Prion and diseases, Volume 2, Animal, humans and the environment*, (2013) pp 59-72, ed. Zou WQ., Gambetti P. Publisher Springer Science + Business Media New York.
2. **Notari S**, Xiao X, Shimoji M, Yuan J, Bi H, Cali I, Kong Q, Zou WQ. Variant Creutzfeldt–Jakob Disease. *Encyclopedia of movement disorders* (2010), pp 315–320 ed. Kompoliti K and Verhagen L. Publisher Academic Press-Elsevier, Oxford, UK.
1. Parchi P, **Notari S**, Strammiello R, Capellari S. History and state of the art of PrP-res "typing" in Creutzfeldt-Jakob disease. *Prions, food and drug safety* (2005), pp 77–95 ed. Kitamoto T. Publisher Springer Tokyo.

ATTIVITÀ DI RELATORE A CONGRESSI E CONVEGNI NAZIONALI E INTERNAZIONALI

Sessione Orale

12. Cracco L, Xiao X, Nemani SK, Lavrich J, Cali I, Ghetti B, **Notari S**, Surewicz WK, Gambetti P. Accumulation of covalently-linked multimers of internal prion protein fragments in two major subtypes of Gerstmann-Sträussler-Scheinker disease. *International conference "Prion* 2019". Edmonton, Canada, May 21–24, 2019.
11. **Notari S.** Variably protease-sensitive prionopathy: a new sporadic prion disease with tau involvement. *CJD 2014 and the Twelfth Annual CJD Foundation Family Conference*. Washington D.C., July 11–13, 2014.
10. Moda F, Gambetti P, Catania M, Marambio LC, Maderna E, **Notari S**, Park KW, Pan I, Haik S, Brandel JP, Ironside JW, Knight RS, Suardi S, Tagliavini F, Soto C. Prion detection in urine of patients with variant Creutzfeldt-Jakob disease: an update. *International conference "Prion* 2014". Trieste, Italy, May 27–30, 2014.

9. Moda F, **Notari S**, Gambetti P, Fugnanesi V, Park KW, Morbin M, Suardi S, Tagliavini F, Soto C. Prion detection in urine of patients with variant Creutzfeldt-Jakob disease. *International conference "Prion* 2013". Banff, Canada, May 26–29, 2013.

8. Gambetti P, Zou WQ, **Notari S.** Variably Protease Sensitive Prionopathy in 2013. *89th Annual Meeting of the American Association of Neuropathologists*. Charleston, North Carolina, USA, June 20–23, 2013.

7. Cali I, Puoti G, Cracco L, Iyer S, Langeveld JP, Kitamoto T, **Notari S**, Zou WQ, Gambetti P. Co-occurrence of distinct types of scrapie prion protein in sporadic Creutzfeldt-Jakob disease *89th Annual Meeting of the American Association of Neuropathologists*. Charleston, North Carolina, USA, June 20–23, 2013.

6. Gambetti P, **Notari S**, Cracco L, Cali I, Kong Q, Zou WQ. Prion strains in human prion diseases: variably protease-sensitive prionopathy compared with other sporadic prion diseases. *International conference "Prion 2012"*. Amsterdam, Netherlands, May 9–12, 2012.

5. Gambetti P, Zou WQ, Torres JM, Soto C, **Notari S**, Espinosa JC, Xiao X. Variably protease-sensitive prionopathy: Transmissibility and PMCA studies. *International conference "Prion 2011"*. Montreal, Canada, May 16–19, 2011.

4. Gambetti P, **Notari S**, Qing L, Dagdanova A, Zou WQ, Pocchiari M, McAnulty P, Dogterom A, Weissmann C, Chen SG, Kong Q. Prion Infectivity in Human Urine. *International conference "Prion 2010" – Pre-Congress WorkShop "Prion Risk 2010 Global Consensus Meeting"*. Salzburg, Austria, September 8–11, 2010.

3. Gambetti P, Puoti G, **Notari S**, Cali I, Zou WQ. A novel atypical prion disease with features of non-Alzheimer dementia. *"The 7th International Conference on Frontotemporal Dementias" -Oral Session-*. Indianapolis, IN, USA, October 6–8, 2010.

2. **Notari S**, Qing L, Dagdanova A, Ilchenko S, Obrenovich ME, Zou WQ, Pocchiari M, Gambetti P, Kong Q, Chen SG. Human urine and PrP. *International Conference "Prion 2009"*. Thessaloniki-Chalkidiki, Greece, 23–25 September, 2009.

1. Parchi P, **Notari S**, Strammiello R, Capellari S. History and state of the art of PrP-res "typing" in Creutzfeldt-Jackob diseases. *International Symposium of Prion Diseases for Food and Drug Safety*. Sendai, Japan, October 31–November 02, 2004.

Sessione Poster

23. Lyon A, Pritzkow S, **Notari S**, Appleby B, Gambetti P and Soto C. High efficiency detection of all prion subtypes of sporadic Creutzfeldt Jakob disease by PMCA. *International conference "Prion 2019*". Edmonton, Canada, May 21–24, 2019.

22. **Notari S**, Moda F, Cali I, Lavrich J, Tagliavini F, Soto C, Gambetti P. PMCA-replicated PrP^{Sc} in urine of vCJD patients maintains strain characteristics of brain PrP^{Sc}: Transmission study. *International conference "Prion 2018"*. Santiago de Compostela, Spain, May 22-25, 2018.

21. **Notari S**, Cracco L, Nemani SN, Ghetti B, Kong Q, Gambetti P. Transmission study of human prion diseases in PrP glycan-KO transgenic mice. *International conference "Prion 2017*". Edinburgh, Scotland, UK, May 23-26, 2017.

20. Camacho MV, Telling G, Gambetti P, **Notari S**. Role of PrP glycosylation in the human prion replication: a PMCA study. *International conference "Prion 2017"*. Edinburgh, Scotland, UK, May 23-26, 2017.

19. Cracco L, **Notari S**, Cali I, Kitamoto T, Bonnin J, Mastrianni JA, Ghetti B, Pierluigi Gambetti P. The comparative study of protease-resistant prion protein typically associated with CJD and GSS reveals an unexpected basic similarity. *93rd Annual Meeting of the American Association of Neuropathologists*. Garden Grove, California, USA, June 08-11, 2017.

18. **Notari S**, Qing L, Kong Q, Camacho MV, Mastrianni JA, Zou W, Gambetti P. New studies on the characteristics of VPSPr: PrP^{Sc} and PrP^{C}. *International conference "Prion 2014"*. Trieste, Italy, May 27–30, 2014.

17. Cannon A, Lin W, Gambetti P, **Notari S**, Pedraza O, Lucas JA, Graff-Radford NR, Ferman TJ, Dickson DW. Case study of concurrent prion disease and amyotrophic lateral sclerosis. *89th Annual*

Meeting of the American Association of Neuropathologists. Charleston, North Carolina, USA, June 20–23, 2013.

16. Bonnin J, Murrell JR, Zou WQ, Gambetti P, **Notari S**, Ghetti B. Variably Protease-Sensitive Prionopathy: A diagnostic challenge. *89th Annual Meeting of the American Association of Neuropathologists*. Charleston, North Carolina, USA, June 20–23, 2013.

15. Saverioni D, **Notari S**, Capellari S, Parchi P. Analyses of PrP^{Sc} aggregation state and protease-resistance in human prions. *International conference "Prion 2011"*. Montreal, Canada, May 16–19, 2011.

14. Gambetti P, Puoti G, **Notari S**, Cali I, Zou WQ. A novel atypical prion disease with features of non-Alzheimer dementia. *International Conference of Frontotemporal Dementias*. Indianapolis, Indiana, USA, October 6–8, 2010.

13. Principe S, Cardone F, Di Francesco L, Giorgi A, Mignogna G, Sbriccoli M, Galeno R, **Notari S**, Capellari S, Parchi P, Rappsilber J, Maras B, Schinina' ME, Pocchiari M. POCCHIARI. The role of PrP and other proteins in prion diseases. In: *Joint Meeting XLV Congress of the Italian Association of Neuropathology (AINP) XXXV Congress of the Italian Association for Research on Brain Aging (AIRIC)*. Bologna, Italy,, June 3 – 6, 2009. CLINICAL NEUROPATHOLOGY, vol. 28 part 3, p. 238, ISSN: 0722-5091,

12. Capellari S, **Notari S**, Cescatti M, Pegoraro E, Pantieri R, Michelacci R, Parchi P. CJD associated with the E200K mutation with valine at codon 129 on the mutated allele and methionine on the wild type allele: Report of two cases. *International Conference "Prion 2007"*. Edinburgh, Scotland, UK, September 26–28, 2007.

11. Principe S, Schininà ME, Maras B, Cosentino D, Liu Q, **Notari S**, Capellari S, Parchi P, Cardone F. Quantitative mass spectrometry analysis of the pathological PrP allotypes present in the brain of gCJD affected individuals. *International Conference "Prion 2007"*. Edinburgh, Scotland, UK, September 26–28, 2007.

10. **Notari S**, Capellari S, Langeveld JP, Giese A, Gambetti P, Kretzschmar HA, Parchi P. Human PrP^{Sc} "typing" pitfalls associated with the use of type 1 selective antibodies combined with relative inefficient hydrolysis of PrP^{Sc} by proteinase K. *International Conference "Prion 2006"*. Turin, Italy, October 4–6, 2006.

9. **Notari S**, Capellari S, Giese A, Grassi J, Ghetti B, Gambetti P, Kretzschmar H, Parchi P. Heterogeneity of truncated fragment distinct from PrP27-30 correlates with clinico-pathological subtypes of Creutzfeldt-Jakob disease. *International Conference "Prion 2005: Between fundamentals and society's needs"*. Düsseldorf, Germany, October 19–21, 2005.

8. Principe S, Dimiziani L, **Notari S**, Liu QG, Cardone F, De Pascalis A, Capellari S, Roepstorff P, Maras B, Parchi P, Schininà ME, Pocchiari M. Quantitative mass spectrometry analysis of the PrPTSE allotypes present in the brain of a diseased individual carrying the R208H mutation. *International Conference "Prion 2005: Between fundamentals and society's needs"*. Düsseldorf, Germany, October 19–21, 2005.

7. Parchi P, **Notari S**, Strammiello R, Capellari S. Further advances in the molecular and pathological diagnosis of sporadic Creutzfeldt-Jakob disease subtypes. *International Symposium on Prion Diseases. For Food and Drug Safety*. Sendai, Japan, October 31–November 2, 2004.

6. **Notari S**, Capellari S, Giese A, Westner I, Ghetti B, Gambetti P, Kretzschmar H, Parchi P. Effects of different experimental conditions on the electrophoretic profile of the PrP^{Sc} core generated by protease digestion in sporadic CJD. *International Conference "Prion Diseases"*. Munich, Germany, October 8–10, 2003.

5. **Notari S**, Capellari S, Giese A, Windl O, Piccardo P, Baruzzi A, Ghetti B, Gambetti P, Kretzschmar HA, Parchi P. pH effect on the PrP^{Sc} core fragment generated by proteinase K digestion: implication for molecular classification of CJD. *"International TSE Conference"*. Edinburgh, Scotland, UK, September 15–18, 2002.

4. Poli A, Lucchi R, Caciagli F, Storto M, **Notari S**, Nicoletti F, Casabona G. Preferential expression of group-II metabotropic glutamate receptors in the goldfish brain. *Annual Meeting of Society for Neuroscience*. Los Angeles, USA, November 7–12, 1998.

3. Poli A, Lucchi R, **Notari S**, Pierantozzi S, Caciagli F, Di Iorio P, Gandolfi O. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced injury in goldfish cerebellum is associated with

increases of glial fibrillary acidic protein. *Annual Meeting of Society for Neuroscience*. New Orleans, USA, October 25–30, 1997.

2. Avitabile E, **Notari S,** Campedelli GC. Ruolo della proteina UL20 nella esocitosi del virus herpes simplex e delle glicoproteine virali. *Congresso Società Italiana di Microbiologia Generale e Biotecnologie Microbiche (SIMGBM)*, Italy, September 26–30, 1994.

1. Lucchi R, Poli A, **Notari S**, Barnabei O. Adenosine receptors mediate inhibition of transmitter release in goldfish cerebellum. *Purine 92, Annual Meeting-Pharmacology and clinical application*. Milano, Italy, June 21–24, 1992.

Data: 07/09/2022 Luogo: Reggio Emilia